Trials / Enrolling By Invitation
Enrolling By InvitationNCT06874894
Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)
Thromboembolic and Bleeding Risk During Anticoagulant Treatment in Asian Patents With Atrial Fibrillation
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,021 (estimated)
- Sponsor
- Chung-Ang University Hosptial, Chung-Ang University College of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Months
- Healthy volunteers
- Not accepted
Summary
This study was design to investigate the efficacy and safety of NOAC therapy in Koreans
Detailed description
East Asians have demonstrated a higher bleeding tendency compared to Western populations during an anticoagulation. Consequently, East Asians have been prescribed as a relatively weaker treatment regimens based on this evidence. Therefore, the TARGET-AF study aims to verify the efficacy and safety of NOAC therapy using biomarkers including TEG®-6S point-of-care device in Koreans
Conditions
Timeline
- Start date
- 2022-05-25
- Primary completion
- 2026-08-30
- Completion
- 2026-08-30
- First posted
- 2025-03-13
- Last updated
- 2025-12-29
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06874894. Inclusion in this directory is not an endorsement.